Navigation Links
Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
Date:4/21/2009

t Circassia

Circassia is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's anti-allergy products offer potential major clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is also high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition.

ToleroMune technology has additional potential regulatory and supply benefits for Circassia. Its state-of-the-art manufacturing fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments.

Circassia has a highly experienced management team with a proven track record in product development and commercialization. Having successfully completed two fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

    For more information please visithttp://www.circassia.co.uk.

    Contacts

    Steve Harris                 Rob Budge
    CEO                          RJB Communications
    Circassia Tel:                       +44-(0)1865-760969
    Tel: +44-(0)1865-784574      Mobile: +44-(0)7710-741241


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
2. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
3. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
4. American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast
5. Study Says Allergy Shots Help Children, Reduce Health Care Costs
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
8. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
9. Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth
10. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014  PTC Therapeutics, Inc. (NASDAQ: ... it approved non-statutory stock options to purchase an aggregate ... new employees. The awards were made pursuant to the ... new hires, employment compensation. The inducement grants ... 2014 and are being made as an inducement material ...
(Date:8/1/2014)... 2014  With monumental health reform coming into effect, ... language. Clinical efficacy is no longer the sole driver ... like PCORI are directing roughly $1 billion a year ... and environments, the federal healthcare ecosystem is changing, and ... outcomes and managed markets to the right people in ...
(Date:8/1/2014)... LAVAL, Quebec and NEW YORK ... Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management, L.P. ... by Allergan, Inc. (NYSE: AGN ) in ... Pershing Square regarding the tender offer rules.  ... an attempt to interfere with shareholders, efforts to call ...
Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
... Reportlinker.com announces that a new market research ... Insulin- Western Europe ... package contains 14 insulin market analyses from ... Denmark, Finland, France, Germany, Ireland, Italy, the ...
... Calif., July 31, 2011 Accuray Incorporated ... radiation oncology company, announced today that it will showcase ... TomoTherapy® Radiation Therapy Treatment System in the ... Association of Physicists in Medicine (AAPM)/Canadian Organization of Medical ...
Cached Medicine Technology:Insulin- Western Europe 2Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 2Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 3Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 4
(Date:8/1/2014)... Although most people are aware of the need ... is particularly important for women. Changes to hormone levels ... ways. Hormones can affect the blood supply to the ... receive nutrients essential to fight infection. In addition, changing ... produced by plaque bacteria, increasing the risk of inflammation ...
(Date:8/1/2014)... 02, 2014 The successful development of ... business of Guangdong FODAY Automobile Co.,LTD. As early as ... had already organized an excellent team to develop a ... detailed, in-depth technical plans. The company’s vice president Liming ... the direct involvement of the specific arrangement and the ...
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... top bridesmaid dresses online. At the moment, all the ... 52% off. According to the company’s senior spokesman, the special ... The company’s stock is limited. Those who are thinking of ... soon as possible. All its products are delicately made by ...
(Date:8/1/2014)... August 01, 2014 Cannabis use among young ... aged 14 to 17 having used marijuana at least once ... their slogan “Say ‘No’ to Drugs, Say ‘Yes to Life,’ ... out to youth this summer with factual information about drugs, ... six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation (JPML) issued ... strokes, heart attacks, and other injuries in men who ... as the transferee judge and ordered what could be ... , As one of his first organizing acts, Judge ... who will move the litigation forward on behalf of ...
Breaking Medicine News(10 mins):Health News:Midtown Dentistry Renews Call for Women to Look After Their Dental Health 2Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2
... Dr. Hungerford is ... invasive single as well as double hip replacement procedures. , ... (Vocus) June 29, 2009 -- Noted orthopedic surgeon Marc ... hospital,s Medical Director of Joint Replacement and Reconstruction, Dr. Thomas Whitten, Chief of Orthopedics at ...
... the victims of these falls, CDC says , MONDAY, ... 47,000 elderly Americans are treated at hospital emergency departments ... according to a federal government study released Monday. , ... day. , U.S. Centers for Disease Control and Prevention ...
... the 1600s quinine was the first effective treatment in the ... commonly used treatment against this devastating disease. But the drug ... can range from sickness and headaches to blindness, deafness and ... knew why. Scientists at The University of Nottingham have ...
... emergency departments first sites for savings ... CalRHIO announced today that it has selected the RAND ... measure savings resulting from physicians having secure electronic access to ... The first phase of the initiative will measure savings in ...
... N.C., June 29 Carolinas HealthCare System ... growth and development of cardiovascular services in North and South ... Sanger Heart and Vascular Institute (SHVI) represents a ... and Vascular Institute. The Institute will continue serving as a ...
... Medicaid Funding Boost Merely Scratches Surface in Terms of Meeting ... In summing up the 2009 session of the Texas ... by Governor Rick Perry, the Texas Health Care Association (THCA) ... ($60 million general revenue) for Medicaid-financed nursing home care, substantially ...
Cached Medicine News:Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 2Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 3Health News:47,000 Elderly Hurt in Walker, Cane Mishaps Each Year 2Health News:Breakthrough in combating the side effects of quinine 2Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 2Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 3Health News:Sanger Clinic Lends Its Name to New Heart Care Institute Serving NC and SC 2Health News:THCA on 2009 Legislative Session: Seniors' Medicaid-Financed Nursing Home Care Requires Substantially More Investment as Population Ages, Care Needs Grow 2
... For Excellent Drainage PLUS Greater Patient ... BLAKE Drains are white, radiopaque silicone drains ... a solid core center. Their other components ... extension tubing and an adapter. The drains ...
Used for percutaneous placement of laparoscopic surgical instruments. Check-Flo® valve provides a secure seal around the instruments to be introduced. Supplied sterile in peel-open packages. Inte...
Used for internal biliary drainage. Supplied sterile in peel-open packages. Intended for one-time use....
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: